Evolution and development of potent monobactam sulfonate candidate IMBZ18g as a dual inhibitor against MDR Gram-negative bacteria producing ESBLs

• Main Authors: Zhiwen Li (Author), Zhihao Guo (Author), Xi Lu (Author), Xican Ma (Author), Xiukun Wang (Author), Rui Zhang (Author), Xinxin Hu (Author), Yanxiang Wang (Author), Jing Pang (Author), Tianyun Fan (Author), Yonghua Liu (Author), Sheng Tang (Author), Haigen Fu (Author), Jingpu Zhang (Author), Yinghong Li (Author), Xuefu You (Author), Danqing Song (Author)
• Format: Book
• Published: Elsevier, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A series of new monobactam sulfonates is continuously synthesized and evaluated for their antimicrobial efficacies against Gram-negative bacteria. Compound 33a (IMBZ18G) is highly effective in vitro and in vivo against clinically intractable multi-drug-resistant (MDR) Gram-negative strains, with a h...